RxDoctor Payments Data

Philip Bacidore, DO

Cardiovascular Disease · Vincennes, INNPI 1891793634

Payments from drug & device makers

$2,134in general payments, 2019–2025

Across 123 payments — averaging $17.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$348
  • Actelion Pharmaceuticals US, Inc.$284
  • AstraZeneca$253
  • Novartis$200
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$179
  • Amgen$162
  • plus $709 from 22 others

What the payments were for

  • Food & beverage$2,134100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,134 in reported general payments places this provider in the 45th percentile of 408 cardiovascular disease providers in Indiana.

See all cardiovascular disease providers in Indiana

Medicare billing

Part B allowed, 2024
$170,631
Medicare patients
1,080
Services billed
1,995

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban385$375,909
XareltoRivaroxaban221$226,343
EntrestoSacubitril/Valsartan139$159,754
Repatha SureclickEvolocumab67$58,983
JardianceEmpagliflozin39$40,580
FarxigaDapagliflozin Propanediol30$32,450
BrilintaTicagrelor33$31,270
Praluent PenAlirocumab24$13,583
Metoprolol Succinate836$9,311
Diltiazem 24hr Er (Cd)Diltiazem Hcl220$5,775
Atorvastatin Calcium458$3,561
Propafenone Hcl69$3,354
ClopidogrelClopidogrel Bisulfate294$3,192
Amlodipine Besylate622$2,987
Isosorbide Mononitrate ErIsosorbide Mononitrate246$2,559

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$60$375,909385 claims
Johnson & JohnsonXarelto$29$226,343221 claims
NovartisEntresto$200$159,754139 claims
AstraZenecaFarxiga, Brilinta$253$63,72063 claims
Boehringer IngelheimJardiance$79$40,58039 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 408 cardiovascular disease providers in Indiana.

Other cardiovascular disease in Vincennes

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →